Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma

Sponsor
Fudan University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02526043
Collaborator
(none)
180
1
2
88
2

Study Details

Study Description

Brief Summary

The purpose of the study is to observe the curative effect and safety of laparoscopic versus open liver resection for hepatocellular carcinoma.

Condition or Disease Intervention/Treatment Phase
  • Procedure: laparoscopic hepatectomy
  • Procedure: Open hepatectomy
N/A

Detailed Description

Liver resection is the most important treatment of hepatocellular carcinoma (HCC). Open hepatectomy was regarded as a giant surgery because of its big incision, influence of the liver function, and long hospital stay. Laparoscopic hepatectomy was widely used since it was reported by Reich in 1991. With the constant innovation of laparoscopic technique and equipment, there is no penalty area in laparoscopic hepatectomy. The Louisville consensus proposed that the best indication for laparoscopic hepatectomy was the tumor diameter < 5cm, located in segment II-VI.

Previous studies shows that compared with the open surgery, laparoscopic hepatectomy has the advantages of shorter operation time, less bleeding, shorter hospitalization time. The mortality, mobility, the overall survival and the disease-free survival was same in these two groups.

So far, however, the curative effect and safety research of laparoscopic versus open liver resection for HCC is limited to retrospective study and case-control study. A prospective, randomized, controlled study is urgently needed.

This study was proceeded to observe the curative effect and safety of laparoscopic versus open liver resection for HCC.

Study Design

Study Type:
Interventional
Actual Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
A Prospective Randomized Control Trail of Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma
Study Start Date :
Aug 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: laparoscopic hepatectomy

The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery

Procedure: laparoscopic hepatectomy
The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy

Experimental: Open hepatectomy

The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery

Procedure: Open hepatectomy
The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery

Outcome Measures

Primary Outcome Measures

  1. Overall survival [5 years]

    The overall survival of HCC patients after operation

Secondary Outcome Measures

  1. Disease free survival [5 years]

    The disease free survival of HCC patients after operation

  2. Incidence of postoperative complications [1 month]

    Incidence of postoperative complications

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Diagnosis was HCC

  2. The tumor was located in segment: II, III, IVb, V, VI

  3. The tumor diameter < 5cm

  4. Without thrombosis in the portal vein, hepatic vein or bile duct

  5. Without intrahepatic and systemic metastasis

  6. The Child-pugh score was A-B7

  7. The ASA(American Society of Anesthesiologists) score was I-III

  8. The patient age was between 18-75

  9. Sign the informed consent, and can fully understand the research content

Exclusion Criteria:
  1. Have surgery contraindications

  2. Pregnant or lactating women

  3. The Child-pugh score was B8-C

  4. The ASA(American Society of Anesthesiologists) score was IV-V

  5. With other malignant tumor

  6. With mental illness

  7. Participated in other clinical trials in the last three months

  8. Underwent other treatments(chemotherapy or radiotherapy) before operation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huashan hospital Shanghai China 200040

Sponsors and Collaborators

  • Fudan University

Investigators

  • Principal Investigator: Lunxiu Qin, MD, Department of general surgery, Huashan hospital, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lunxiu Qin, Department of general surgery, Huashan hospital, Fudan University
ClinicalTrials.gov Identifier:
NCT02526043
Other Study ID Numbers:
  • Huashan 002
First Posted:
Aug 18, 2015
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2022